About us

partner with us

Improving the lives of patients by developing proprietary, innovative

In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.
Clinical trials completed and medical device certification obtained, enterprise value at EUR 180m. Exit strategy: second public offering on a selected stock exchange abroad e.g. Euronext, London Stock Exchange, alternatively a merger & acquisition deal

Our Partners

  • Merck

    In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.

  • Pfizer Eastern Europe

    In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.

  • Alcon

    In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.

  • Community Foundation

    In the long run, the Company aims to leverage the platform it has created to develop additional therapies. These may include expanding applications for other forms of type Our mission is to raise awareness and transform the treatment of severe aortic regurgitation.

become our partner

Improving the lives of patients
by developing proprietary, innovative

Prof. Paweł Buszman, MD, PhD, EMBA

founder, CEO, Project Lead and Principal Investigator

Founder of American Heart of Poland – the largest network of cardiovascular centers in Europe – successful divestment through acquisition by a large international group. Manager and Principal investigator in numerous pre-clinical and clinical trials. Author of over 200 publications.

Internationally acclaimed interventional cardiologist and entrepreneur granted multiple awards, including EY Entrepreneur of the Year. Member of many international organizations, including the European Society of Cardiology (FECC), the American College of Cardiology (FACC) and the Society of Cardiac Angiography and Interventions (FSCAI). Alumnus of the TRIUM Executive MBA programme jointly organized by LSE, HEC and NYSU.